The company has not filed an annual or quarterly report since its FY2021 10-K, filed Jun 29, 2021. Its latest SEC filing is a 15-12B from Jul 30, 2021.
10-K for FY2021, filed Jun 29, 2021
The sections below describe the company as of the FY2021 annual report.
Sells prescription and over-the-counter medicines, healthcare products and medical services through pharmacies and online platforms to consumers, and distributes pharmaceutical products to drug vendors and hospitals.
10-K for FY2021, filed Jun 29, 2021We are a retailer and distributor of pharmaceutical and other healthcare products typically found in retail pharmacies in the People’s…View ↗
We currently operate in four business segments in China: (1) retail drugstores, (2) online pharmacy, (3) wholesale business selling…View ↗
Our stores provide customers with a wide variety of pharmaceutical products, including prescription and over-the-counter (“OTC”) drugs…View ↗
Since May 2010, we have been retailing OTC drugs and nutritional supplements on the Internet at www.dada360.com. Before November 2015, our…View ↗
Since acquiring Jiuxin Medicine in August 2011, we have been distributing third-party products primarily to drug distributors throughout…View ↗
Retail customers shop in the company’s pharmacies, and online consumers buy through its website and third-party platforms. Wholesale sales go mainly to trading companies that resell to pharmacies, with some sales to hospitals and pharmacies.
10-K for FY2021, filed Jun 29, 2021Our stores provide customers with a wide variety of pharmaceutical products, including prescription and over-the-counter (“OTC”) drugs…View ↗
Since May 2010, we have been retailing OTC drugs and nutritional supplements on the Internet at www.dada360.com. Before November 2015, our…View ↗
Since acquiring Jiuxin Medicine in August 2011, we have been distributing third-party products primarily to drug distributors throughout…View ↗
Our wholesale customers are primarily third-party trading companies that purchase from us to resell to pharmacies throughout China. We also…View ↗
8-K, filed Jul 28, 2021
Under Rule 5810(c)(3)(A), the Company will be provided a compliance period of 180 calendar days, until January 24, 2022, to regain…View ↗
Loading...
